At the end of 2021, the market for anti-infective vaccines was estimated to be worth roughly $51.0 billion. By 2032, the market is anticipated to grow at a 12.3% CAGR and reach a value of US$ 168.7 Billion.

By exposing the immune system to pathogens (bacteria or viruses) that cause disease when they are dormant or inactive, vaccinations work to reduce the chance of contracting certain diseases and infections. This procedure promotes the production of antibodies, which can provide immunity from a number of ailments and illnesses.

Depending on the target patient's requirements and how the immune system responds to the vaccination. There are many distinct types of vaccinations, including inactivated vaccines, live/attenuated vaccines, and conjugate vaccines, for treating illnesses such bacterial/viral infection and influenza.

Anti-Infective Vaccines Market: Segmentation

Valuable information covered in the FMI’s Anti-Infective Vaccines market report has been segregated into key segments and sub-segments.

By Type:

  • Inactivated Vaccines
  • Conjugate Vaccines
  • Live/Attenuated Vaccines
  • Others

By Application:

  • Bacterial Diseases
  • Viral Diseases
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Read More Details About Report@ https://www.futuremarketinsights.com/reports/anti-infective-vaccines-market

Anti-Infective Vaccines Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Anti-Infective Vaccines market. Competitive information detailed in the Anti-Infective Vaccines market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Anti-Infective Vaccines market report.

Key players covered in the report include:

  • Barr Labs, Inc.,
  • Emergent BioDefense Operations Lansing Inc.,
  • Organon Teknika Corp LLC,
  • Sanofi Pasteur, Inc.,
  • GlaxoSmithKline Biologicals, Merck & Co, Inc.,
  • CSL Limited, MedImmune LLC,
  • ID Biomedical Corp.,
  • Novartis Vaccines and Diagnostics Limited,
  • Protein Sciences Corporation,
  • Intercell Biomedical,
  • Wyeth Pharmaceuticals, Inc.,
  • MassBiologics,
  •  Berna Biotech, Ltd. and others.
  • GlaxoSmithKline Pharmaceuticals Ltd., VaxGen